UTHealth Houston-developed cancer therapy platform takes major step toward clinical translation
CrossBridge Bio, a biotechnology company developing next-generation antibody-drug conjugates based on discoveries by researchers at UTHealth Houston, is taking a major step toward clinical translation after being acquired by Eli Lilly. The dual-payload antibody-drug conjugate technology was originally created by…
An lab discovers novel nasal treatment for influenza
New data from researchers at the Brown Foundation Institute of Molecular Medicine exploring novel therapeutic approaches to treating Influenza A viruses has been published in Nature Communications. The paper (external link), titled “An intranasally administered IgM protects against antigenically distinct subtypes…
University researchers receive more than $5 million from CPRIT
Three UTHealth Houston researchers, including two from McGovern Medical School, received more than $5 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT) (external link), furthering the state’s mission to prevent and treat cancer through innovative…